MYC and neoplasm: Tumor cells upregulate most glycolytic enzymes due to increased c‐Myc and hypoxia‐inducible factor 1 alpha (HIF‐1α) transcriptional activity, insufficient control by p53 and other tumor suppressors, and oncogenes such as mutant Kirsten rat sarcoma virus (KRAS).